Диссертация (1139510), страница 53
Текст из файла (страница 53)
2001 Sep; 104(3):173-92.198. Kirchheiner J, Nickchen K, Sasse J, Bauer M, Roots I, Brockmöller J. A 40basepair VNTR polymorphism in the dopamine transporter (DAT1) gene and the283rapid response to antidepressant treatment. Pharmacogenomics J. 2007Feb;7(1):48-55.199. Kirsch I, Antonuccio D: Antidepressants versus placebos: meaningfuladvantages are lacking. Psych Times, September 19, 2002.200. Kirsch I, Deacon B, Huedo-Medina TB, Moore TJ, Johnson BT: Initialseverity and antidepressant benefits: a meta-analysis of data submitted to the Foodand Drug Administration. PLoS Med 2008;5:e45.201. Kirsch I, Moore T, Scoboria A, Nichols S: The emperor’s new drugs: ananalysis of antidepressant medication data submitted to the U.S.
Food and DrugAdministration. Prev Treat 2002;5:article 23.202. Kirsch I, Scoboria A, Moore TJ: Antidepressants and placebos: secrets,revelations, and unanswered questions. Prev Treat 2002;5:article 33.203. Kleeblatt J, Betzler F, Kilarski LL, Bschor T, Köhler S. Efficacy of offlabel augmentation in unipolar depression: A systematic review of the evidence.Eur Neuropsychopharmacol. 2017 May;27(5):423-441.204.
Kocsis JH, Mason BJ, Frances AJ, Sweeney J, Mann JJ, Marin D.Prediction of response of chronic depression to imipramine. J Affect Disord.1989;17:255-260.205. Kornstein SG, Schatzberg AF, Thase ME, et al. Gender differences inchronic major and double depression. J Affect Disord. 2000;60:1-11.206. Kotov R, Krueger RF, Watson DA. A paradigm shift in psychiatricclassification: the Hierarchical Taxonomy Of Psychopathology (HiTOP). WorldPsychiatry.
2018 Feb;17(1):24-25.207. Kotov R, Krueger RF et al. The Hierarchical Taxonomy of Psychopathology(HiTOP): A dimensional alternative to traditional nosologies. J AbnormPsychol. 2017 May;126(4):454-477.208. Kraft JB, Peters EJ, Slager SL, Jenkins GD, Reinalda MS, McGrath PJ,Hamilton SP.Analysis of association between the serotonin transporter andantidepressant response in a large clinical sample. Biol Psychiatry.
2007 Mar15;61(6):734-42.209. Kraft JB, Slager SL, McGrath PJ, Hamilton SP. Sequence analysis of theserotonin transporter and associations with antidepressant response. BiolPsychiatry 2005; 58: 374– 81.210. Kunugi H, Hattori M, Kato T, Tatsumi M, Sakai T, Sasaki T et al. Serotonintransporter gene polymorphisms: ethnic difference and possible association withbipolar affective disorder.
Mol Psychiatry 1997; 2: 457–462211. Lamers F., de Jonge P., Nolen W.A., Smit J.H., Zitman F.G., Beekman A.T.F.Identifying depressive subtypes in a large cohort study: Results from the284Netherlands Study of Depression and Anxiety (NESDA) J ClinPsychiatry. 2010;71:1582–1589.212. Lanza ST and Rhoades BL. Latent Class Analysis: An AlternativePerspective on Subgroup Analysis in Prevention and Treatment.
Prev Sci. 2013Apr; 14(2): 157–168.213. Lee MS, Lee HY, Lee HJ, et al. Serotonin transporter promoter genepolymorphism and long-term outcome of antidepressant treatment. PsychiatrGenet. 2004;14:111–5.214. Lemonde S, Turecki G, Bakish D, Du L, Hrdina PD, Bown CD, Sequeira A,Kushwaha N, Morris SJ, Basak A, Ou XM, Albert PR.
Impaired repression at a 5hydroxytryptamine 1A receptor gene polymorphism associated with majordepression and suicide. J Neurosci. 2003 Sep 24;23(25):8788-99.215. Leuchter AF, Cook IA, Hamilton SP, et al. Biomarkers to predictantidepressant response. Curr Psychiatry Rep. 2010;12:553-562.216. Levin GM, Bowles TM, Ehret MJ, Langaee T, Tan JY, Johnson JA, MillardWJ. Mol Diagn Ther. 2007;11(3):155-60. Assessment of human serotonin 1Areceptor polymorphisms and SSRI responsiveness.217. Lewis CM, Ng MY, Butler AW, Cohen-Woods S, Uher R, Pirlo K, et al.Genome-wide association study of major recurrent depression in the UKpopulation. Am J Psychiatry.
2010;167:949–57.218. Linde K, Kriston L, Rucker G et al. Efficacy and Acceptability ofPharmacological Treatments for Depressive Disorders in Primary Care: SystematicReview and Network Meta-Analysis. Ann Fam Med 2015;13:69-79.219. Lindpaintner K. Review Pharmacogenetics and pharmacogenomics in drugdiscovery and development: an overview. Clin Chem Lab Med. 2003 Apr;41(4):398-410.220.
Linnet K, Ejsing TB. A review on the impact of P-glycoprotein on thepenetration of drugs into the brain. Focus on psychotropic drugs. EurNeuropsychopharmacol 2008; 18:157–169221. Linnet K, Ejsing TB. A review on the impact of P-glycoprotein on thepenetration of drugs into the brain. Focus on psychotropic drugs. EurNeuropsychopharmacol 2008; 18:157–169222.
Lockhart P, Guthrie B (2011) Trends in primary care antidepressantprescribing 1995–2007: a longitudinal population database analysis. Br J GenPract 61(590):e565–e572223. Lorenzini KI, Calmy A, Ambrosioni J, Assouline B, Daali Y, Fathi M,Rebsamen M, Desmeules J, Samer C Serotonin syndrome following drug-druginteractions and CYP2D6 and CYP2C19 genetic polymorphisms in an HIV-285infected patient. FAIDS. 2012 Nov 28; 26(18):2417-8.224. Lux, V., & Kendler, K. S. (2010). Deconstructing major depression: avalidation study of the DSM-IV symptomatic criteria.
Psychological medicine,40(10), 1679–90.225. MacDonald TM, McMahon AD, Reid IC, et al. Antidepressant drug use inprimary care: a record linkage study in Tayside, Scotland. British MedicalJournal. 1996;313:860–861.226. Maes M, Libbrecht I, Van Hunsel F, Campens D, Melter HY. Pindolol andmianserin augment the antidepressant activity of fluoxetine in hospitalized majordepressed patients, including those with treatment resistance. J ClinPsychopharmacol. 1999; 19: 177-182227. Maes M, Song C, Lin AH, Bonaccorso S, et al. Negative immunoregulatoryeffects of antidepressants: Inhibition of interferon-gamma and stimulation ofinterleukin-10 secretion.
Neuropsychopharmacology 1999; 20:370–9.228. Mahar, I., Bambico, F. R., Mechawar, N., and Nobrega, J. N. (2014). Stress,serotonin, and hippocampal neurogenesis in relation to depression andantidepressant effects. Neurosci. Biobehav. Rev. 38, 173–192.229. Mahmoud RA , Pandina GJ , Turkoz I , Kosik-Gonzalez C , Canuso CM ,Kujawa MJ , et al . 2007 . Risperidone for treatment-refractory major depressivedisorder: a randomized trial . Ann Intern Med 147 : 593 – 602 .230. Maj M.
Keeping an open attitude toward the RDoC project. WorldPsychiatry. 2014; 13: 1–2.231. Maj, M. (2016). Narrowing the gap between ICD/DSM and RDoCconstructs: possible steps and caveats. World Psychiatry, 15(3), 193–194.232. Malhotra AK, Murphy GM, Kennedy JL. Pharmacogenetics of PsychotropicDrug Response. Am J Psychiatry 2004; 161: 780-96.233. Marcus RN, McQuade RD, Carson WH, Hennicken D, Fava M, SimonJS, Trivedi MH, Thase ME, Berman RM.
The efficacy and safety of aripiprazole asadjunctive therapy in major depressive disorder: a second multicenter, randomized,double-blind, placebo-controlled study. J Clin Psychopharmacol. 2008Apr;28(2):156-65.234. Marquand AF, Wolfers T, Mennes M, Buitelaar J, Beckmann CF. BeyondLumping and Splitting: A Review of Computational Approaches for StratifyingPsychiatric Disorders. Biological Psychiatry.
2016;1(5):433-447.235. Martis S. et al. Multi-ethnic distribution of clinically relevant CYP2Cgenotypes and haplotypes. Pharmacogenomics J. 2013 Aug;13(4):369-77.286236. MaybergHS., Brannan SK., Tekell JL., et al. Regional metabolic effects offluoxetine in major depression: serial changes and relationship to clinicalresponse.
Biol Psychiatry. 2000;48:830–843.237. Mazure, C. M. (1998). Life Stressors as Risk Factors in Depression. ClinicalPsychology: Science and Practice, 5(3), 291–313.238. McIntyre A , Gendron A , McIntyre A . 2007 . Quetiapine adjunct toselective serotonin reuptake inhibitors or venlafaxine in patients with majordepression, comorbid anxiety, and residual depressive symptoms: a randomized,placebo-controlled pilot study . Depress Anxiety 24 : 487 – 494 .239.
McKinnon M, Yucel K, Nazarov A, MacQueen G. A meta-analysisexamining clinical predictors of hippocampal volume in patients with majordepressive disorder. J Psychiatry Neurosci 2009, 34:41–54.240. McNally RJ, Robinaugh DJ, Wu GW, Wang L, Deserno MK, Borsboom D.Mental disorders as causal systems: A network approach to Posttraumatic StressDisorder. Clinical Psychological Science.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
